搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 7 天
时间不限
过去 1 小时
过去 24 小时
过去 30 天
按相关度排序
按时间排序
4 天
U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased ...
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO® (Respiratory ...
BioSpace
3 天
Pfizer Wins FDA Approval of RSV Vaccine for Broader Adult Population
Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age.
4 天
US FDA approves Pfizer's RSV vaccine for adults at increased risk of the disease
The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract ...
2 天
on MSN
GSK reports positive data for RSV shot in younger, at-risk adults
GSK (GSK) reported its RSV vaccine Arexvy elicited a robust immune response in people aged 18 to 49 years who were at ...
tnp.straitstimes
5 天
Vaccine to protect babies from viral respiratory infection
From Nov 1, pregnant women can get a vaccine shot to protect infants against a viral respiratory infection with symptoms like ...
5 天
Pregnant women in Singapore can get jab to protect babies from respiratory infection from Nov 1
Antibodies from the Abrysvo vaccine will be passed from the mothers to the babies. Read more at straitstimes.com.
GlobalData on MSN
3 天
FDA expands Pfizer’s RSV vaccine label to include all high-risk adults
Abrysvo is now approved to prevent lower respiratory tract disease caused by RSV in high-risk adults aged over 18 years.
FiercePharma
3 天
FDA approves Pfizer's RSV shot Abrysvo for all at-risk adults
While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to ...
3 天
FDA Approves Pfizer's Respiratory Syncytial Virus Vaccine Abrysvo For Adults Below 60 Years
Abrysvo (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, to prevent lower ...
Zacks.com on MSN
3 天
PFE Gets FDA Nod for Expanded Use of RSV Vaccine Abrysvo
Pfizer Inc. PFE announced that the FDA has granted approval for the expanded use of its respiratory syncytial virus (RSV) ...
2 天
GSK reports preliminary data for AREXVY
GSK (GSK) announced new preliminary data for AREXVY in adults aged 18-49 at increased risk for lower respiratory tract disease, LRTD, caused by ...
pulmonologyadvisor
2 天
RSV Vaccine Abrysvo Approved for Adults Aged 18 to 59 at Increased Risk
FDA has approved Abrysvo for active immunization for the prevention of lower respiratory tract disease caused by RSV.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈